Learn How Product Teams Allocate Resources to Overcome Challenges from the Pre-Clinical Period to Post-Launch - Blockbuster Brand Resource Allocation

Business Wire, June 30, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38995) has announced the addition of "Blockbuster Brand Resource Allocation (PH85)" to their offering.

Blockbuster Brand Resource Allocation (PH85) provides detailed brand profiles outlining spending and staffing resources for 18 products with annual sales of more than $1 billion. Each profile separates the brand's total marketing budget and headcount into four categories: brand activities, market research, thought leader development and advertising.

The study examines global brand planning strategies as well as examples of European and US commercialization from more than a dozen top pharmaceutical and biotechnology firms.

Compare real-world budget and staffing levels for blockbuster teams at companies of all sizes. Our report provides support for your ideas and helps you prepare for meetings, presentations and strategy discussions with key executives. Compare your large brand against similar product teams' resource allocation levels and benchmark your progress throughout development. Learn how great companies such as Pfizer, Sanofi-Aventis, and Eli Lilly invest in their largest products.

Our reports are ready to use the moment you get them. Skim chapter introductions and subsections to review critical product management concepts. Then read the brand profiles, data analyses, and strategic assessments to gather the details you need to refine and evaluate your brand's resource allocation. Throughout the report, extensive metrics offer in-depth evidence to support your commercialization efforts.

Key Topics Covered Include:

--Profiled Companies and Therapeutic Areas

--Methodology and Definitions

--Blockbuster Brand Marketing: Conclusions and Recommendations

--Global Resource Allocation

Companies Profiled Include:

--Abbott Laboratories

--Amgen

--AstraZeneca

--Berlex

--CV Therapeutics

--Dendreon

--Eli Lilly

--Johnson & Johnson

--Merck KGaA

--Novo Nordisk

--Organon

--Pfizer

--Procter & Gamble

--Roche

--Sanofi-Aventis

--TAP Pharmaceuticals

For more information visit http://www.researchandmarkets.com/reports/c38995